RoslinCT secures £7.25m Scottish Enterprise funding for expansion
Edinburgh-based cell therapy manufacturer RoslinCT has been awarded a Scottish Enterprise research and development grant of up to £7.25 million to digitise its manufacturing operations in Scotland.
The company announced the award on 6 October 2026. The funding forms part of a multi-year programme covering integrated digital systems, data connectivity, and artificial intelligence. RoslinCT has not disclosed the total cost of the project.
What the programme covers
RoslinCT is a contract development and manufacturing organisation (CDMO), producing cell therapies on behalf of companies developing new treatments. These therapies use living cells from patients or donors, with manufacturing processes requiring detailed quality checks and production records.
The programme aims to connect data more closely across RoslinCT’s manufacturing operations. The company says this should improve efficiency and consistency while supporting clients from early development through to commercial production.
Chief executive Peter Coleman said digital technologies were enabling “greater efficiency, consistency and scalability” in cell therapy manufacturing.
The announcement does not specify how artificial intelligence will be used in practice. The benefits outlined are targets for the programme rather than results already achieved.
Advanced therapy manufacturing in Edinburgh
RoslinCT operates from Edinburgh BioQuarter on Little France Road, where it has manufacturing authorisations from the Medicines and Healthcare products Regulatory Agency (MHRA) covering cell therapies for clinical trials and commercial supply.
The company also operates a facility in Hopkinton, Massachusetts, and has 22 specialist cell therapy processing suites across its two locations.
RoslinCT says the digital programme is expected to support job creation and high-value employment in Scotland. It has not announced a number of new positions or a recruitment timetable.
The company traces its origins to the Roslin Institute, associated with the cloning of Dolly the sheep, and is part of healthcare investor GHO Capital’s portfolio. Its services include cell therapy process development, clinical and commercial manufacturing, and stem cell line development.
The grant follows two commercial agreements announced in 2026. In January, RoslinCT signed a manufacturing agreement with BOOST Pharma covering a cell therapy being developed for infants with brittle bone disease.
In July, the company announced a partnership with BlueRock Therapeutics to expand access to clinical-grade pluripotent stem cell lines for cell therapy developers.
Related Scottish business news
